- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07943039
Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.
Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.
Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.
Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Erlie Jiang
- Numero di telefono: +86-15122538106
- Email: jiangerlie@ihcams.ac.cn
Backup dei contatti dello studio
- Nome: Xin Chen
- Numero di telefono: +86-13920985705
- Email: chenxin@ihcams.ac.cn
Luoghi di studio
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Cina, 300020
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.
Descrizione
Inclusion Criteria
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
- gender: no gender limit;
- sibling identical hematopoietic stem cell transplantation;
- fair general status, ECOG score <2 points;
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.
Exclusion Criteria:
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
- history of tumor and treatment for any tumor within the past 3 years;
- Prior hematopoietic stem cell transplantation;
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
- Subjects considered unsuitable for enrollment by the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of acute graft-versus-host disease (aGVHD)
Lasso di tempo: within 100 days after hematopoietic stem cell infusion
|
aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria. |
within 100 days after hematopoietic stem cell infusion
|
|
Incidence of chronic graft-versus-host disease (cGVHD)
Lasso di tempo: 5 years after hematopoietic stem cell transplantation
|
cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines |
5 years after hematopoietic stem cell transplantation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
1-year implantation rate
Lasso di tempo: 1-year
|
The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year |
1-year
|
|
Overall survival rate
Lasso di tempo: 5 years after hematopoietic stem cell transplantation
|
All-cause mortality from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Rejection (AA) or recurrence (malignant)
Lasso di tempo: 5 years after hematopoietic stem cell transplantation
|
Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Incidence of fungal infection
Lasso di tempo: 2 years after hematopoietic stem cell infusion
|
Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of cytomegalovirus infection
Lasso di tempo: 2 years after hematopoietic stem cell infusion
|
Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of Epstein-Barr virus infection
Lasso di tempo: 2 years after hematopoietic stem cell infusion
|
Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Transplant-related mortality
Lasso di tempo: 5 years after hematopoietic stem cell infusion
|
Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion |
5 years after hematopoietic stem cell infusion
|
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Lasso di tempo: 2 years after hematopoietic stem cell infusion
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IIT2026106
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .